What Is CJC-1295 No DAC? Research Evidence & Profile

What Is CJC-1295 No DAC?

CJC-1295 No DAC is a distinct CJC-1295 No DAC catalogue entry that must remain separate from CJC-1295 with DAC. This page identifies the material as Growth Hormone-Releasing Hormone Analog (CJC-1295 No DAC), with physical form Lyophilized powder. The CJC-1295 No DAC identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

12ClinicalTrials.gov query records

15PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for CJC-1295 No DAC is organized around peptide identity comparison, catalogue-level CJC differentiation, signaling-literature review, and analytical peptide characterization. For CJC-1295 No DAC, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT01263717Effects of Growth Hormone Releasing Hormone in HIV	NA	Completed	HIV, HIV Lipodystrophy	2017-10-30
NCT02196831Tesamorelin Effects on Liver Fat and Histology in HIV	NA	Completed	Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)	2020-01-27
NCT03226821Body Composition and Adipose Tissue in HIV	Phase 4	Terminated	HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition	2026-05-19
NCT03276858Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers	Phase 1	Completed	Healthy Volunteers	2018-08-29
NCT07481734Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)	Phase 2	Recruiting	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis	2026-03-19
NCT00608023TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy	Phase 3	Completed	Lipodystrophy, HIV Infections	2022-09-30

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Frontiers in endocrinology · 2026

PMID 42395176

Selected PubMed record

Metabolic dysfunction-associated steatotic liver disease in people with HIV.

Current opinion in HIV and AIDS · 2025 Jul 1

PMID 40397552

Selected PubMed record

Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone.

Domestic animal endocrinology · 1988 Jan

PMID 3147164

Selected PubMed record

Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.

AIDS reviews · 2010 Jan-Mar

PMID 20216906

Selected PubMed record

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight · 2020 Aug 20

PMID 32701508

Selected PubMed record

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

HIV/AIDS (Auckland, N.Z.) · 2011

PMID 22096409

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Growth Hormone-Releasing Hormone Analog (CJC-1295 No DAC)
Available Specifications: 2mg, 5mg, 10mg
Pack Format: 10 Vials
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for CJC-1295 No DAC

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

CJC-1295 No DAC Research Summary

Identity

Growth Hormone-Releasing Hormone Analog (CJC-1295 No DAC); specifications: 2mg, 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

12 registry records and 15 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

CJC-1295 No DAC is represented here by the catalogue identity Growth Hormone-Releasing Hormone Analog (CJC-1295 No DAC). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 2mg, 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for CJC-1295 No DAC is organized around peptide identity comparison, catalogue-level CJC differentiation, signaling-literature review, and analytical peptide characterization. For CJC-1295 No DAC, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 12 ClinicalTrials.gov records and 15 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

CJC-1295 No DAC FAQ

What is CJC-1295 No DAC?

What research records are indexed for CJC-1295 No DAC?

The synchronized query returned 12 ClinicalTrials.gov records and 15 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is CJC-1295 No DAC FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.